NPHS1 and neoplasm: Among the 224 cNF tumors analyzed, there was a dose-dependent reduction in tumor volume at day 28, with mean percent change from baseline of −1.6, −11.9, and −16.7% in the 0.05, 0.15, and 0.5% NFX-179 Topical Gel groups, respectively, compared to −8.0% in the vehicle group (Fig. 3A and table S4).